Wedbush removed Wave Life Sciences (WVE) from its Best List Ideas due to the firm’s investment price discipline. Wedbush has an Outperform rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE:
- Wave Life Sciences price target lowered to $21 from $38 at BofA
- Wave Life Sciences price target lowered to $13 from $27 at Wells Fargo
- Risk-Adjusted Buy Rating on Wave Life Sciences: Differentiated Obesity Mechanism, Reset Valuation, and Long-Term Upside Despite 400 mg Uncertainty
- Wave Life Sciences price target lowered to $39 from $50 at Clear Street
- Wave Life Sciences price target lowered to $25 from $35 at Leerink